Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 on ClinicalTrials.gov · last registry update 2026-09-15
Recruiting now, toward 252 participants. Due to report March 2030, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Development of T2DM. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 14 September 2023 — 3 years so far. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Sponsor type
- Other
- Enrollment
- 252
- Started
- 2023-09-14
- Primary completion
- 2030-03 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-15 | Reporting date moved | 2029-06 → 2030-03 9 months later |
Primary outcome
Development of T2DM
Conditions studied
Glucose Intolerance After a Recent History of Gestational Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.